Targeting NAD+ metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression

Affiliations

• Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
• State Key Laboratory of Organ Failure Research, Guangzhou, 510515, China.
• Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, 510515, China.
• Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
• Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. liuli@i.smu.edu.cn.
• State Key Laboratory of Organ Failure Research, Guangzhou, 510515, China. liuli@i.smu.edu.cn.
• Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, 510515, China. liuli@i.smu.edu.cn.

PMID: 37204655 DOI:  10.1007/s12072-023-10544-7

Abstract

Lowered nicotinamide adenine dinucleotide (NAD+) levels in tumor cells drive tumor hyperprogression during immunotherapy, and its restoration activates immune cells. However, the effect of lenvatinib, a first-line treatment for unresectable hepatocellular carcinoma (HCC), on NAD+metabolism in HCC cells, and the metabolite crosstalk between HCC and immune cells after targeting NAD+metabolism of HCC cells remain unelucidated.

References

• Chen D, Liu J, Zang L, Xiao T, Zhang X, Li Z, et al. Integrated machine learning and bioinformatic analyses constructed a novel stemness-related classifier to predict prognosis and immunotherapy responses for hepatocellular carcinoma patients. Int J Biol Sci. 2022;18(1):360–373.
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
• Vogl TJ, Zangos S, Balzer JO, Nabil M, Rao P, Eichler K, et al. transarterial chemoembolization (tace) in hepatocellular carcinoma: technique, indication and results. Rofo. 2007;179(11):1113–1126.
• Chen S, Zeng X, Su T, Xiao H, Lin M, Peng Z, et al. Combinatory local ablation and immunotherapies for hepatocellular carcinoma: rationale, efficacy, and perspective. Front Immunol. 2022;13:1033000.
• D’Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Curr Opin Oncol. 2021;33(4):386–394.